Primary results from COSMIC-313 demonstrated significantly longer progression-free survival (PFS) with first-line cabozantinib plus nivolumab and ipilimumab versus placebo plus nivolumab and ipilimumab in patients with advanced renal-cell carcinoma (RCC). Final efficacy and safety results, as well as data from exploratory biomarker analyses, are reported here.
Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study
Annals of Oncology | | R.J. Motzer, L. Albiges, S.A.Treviño Aguirre, R. Kanesvaran, P. Centkowski, M.A. Reimers, J.P. Sade, D. Pouessel, E. Biscaldi, E. Esteban, J.Á. Arranz Arija, S.S. Tykodi, M. van Kooten Losio, A. Dighe, H. Ma, V. Valmeekam, A. Simmons, C. Scheffold, S. Andrianova, D.A. Braun, T. Powles, T.K. Choueiri
Topics: kidney-cancer, cervical-cancer, immunotherapy, targeted-therapy, clinical-trials, research